Hansa Pivots to U.S. with SERB Deal and Positive Clinical Data
Out-licensing European rights, sharply higher cash, and a confirmed path to U.S. launch set the stage for a transformative year.
HNSA.ST · Earnings Call · 2026-07-22
Strategic Pivot: Europe out, U.S. in
Hansa Biopharma's Q2 2026 call was less about the quarter's numbers and more about a structural re‑orientation. The company formally closed a EUR 150 million out‑licensing agreement with SERB Pharmaceuticals for Idefirix in Europe and surrounding territories. Renée Aguiar‑Lucander called it a “transformative quarter” — Renée Aguiar-Lucander, Chief Executive Officer · 2026-07-22 and framed the decision as a long‑term strategic choice: “By partnering in Europe, we strengthened the commercial support for Idefirix, both in terms of resources and experience, which will enhance patient access and ensure long‑term success.” — Renée Aguiar-Lucander, Chief Executive Officer · 2026-07-22 The commercial plan now shifts decisively to the United States, where the company's own market access team has already been built out. The transaction dramatically changed the balance sheet. As CFO Adam Cutler noted, pro forma cash after the EUR 110 million upfront payment reached roughly SEK 1.8 billion (~$185 million), financing the U.S. launch and removing near‑term funding uncertainty. This is a marked departure from the prior call, where the CEO was still describing the FDA review as “going very well” but with no mention of a partnered European exit.From Conditional to Full Approval, and a Data‑Rich Summer
The positive top‑line data from the PAES trial — the confirmatory European study — is another pillar of the new narrative. It opens the door to converting conditional approval into full approval next year. Richard Philipson reported the findings at ATC and highlighted that imlifidase patients had a mean eGFR of 51.5 mL/min vs. 19.3 in control, with only five patients dialysis‑dependent at 12 months against 17 in the control arm. This is the kind of clinical evidence that supports both the European MA submission and the U.S. BLA review. On the U.S. front, the PDUFA date of December 19 remains firmly in sight, and the company has made clear it expects a Q1 2027 launch. “We are five months away from the PDUFA of December 19th. Our pre‑launch efforts are in full motion.” — Maria Törnsén, Market Access and Medical Affairs (inferred) · 2026-07-22 The company has also been reinforcing its portfolio optionality — exploring gene therapy collaborations and advancing HNSA‑5487 toward an IND. While no specifics were provided, the newly hired VP of Business Development signals a more systematic approach to inbound interest. The earlier calls had acknowledged that the company lacked dedicated senior resources to pursue these conversations; now that is changing.U.S. Launch Readiness and Market Access Dynamics
Maria Törnsén outlined a detailed pre‑commercial infrastructure: a field‑based market access team covering the top 100 transplant centers, profiling stakeholders and assessing site readiness. The expected U.S. market launch will rely on a deliberate reimbursement pathway — DRG plus outlier payments and an anticipated NTAP application. In the prior quarter's Q&A, Maria explained how this mirrors CAR‑T launch dynamics: “The big benefit we have in the U.S. is that the data available in terms of how many patients are at each center is remarkable.” — Maria Tornsen, Unknown · 2026-02-11 That data‑rich environment is now being translated into concrete launch plans. The market itself is substantial: approximately 100,000 patients on the waitlist, with 7,000 above 98% cPRA. Early adoption is likely to come from high‑volume centers, and the company is already receiving unsolicited patient and physician interest. The strategic logic is clear: by handing European commercialization to SERB, Hansa can focus its own resources on the U.S., where reimbursement is more predictable and the patient population is larger.What Changed, and Why It Matters
The most consequential shift is the re‑focus on the U.S. The SERB deal not only strengthens the balance sheet but also removes the operational drag of managing a fragmented European market with regional reimbursement hurdles — a problem that had weighed on sales and pressured the stock in earlier quarters. As Renée said in closing,The clinical data continues to be remarkably consistent — the Imlifidase arm showed durable kidney function and no graft loss due to AMR. Combined with the positive PAES readout, it significantly de‑risks the U.S. FDA decision. The company is now well‑capitalized, has a clear roadmap, and an experienced team to execute. As the year progresses, the key inflection point is the December PDUFA, and Hansa's trajectory — from a struggling European seller to a launch‑ready U.S. biotech — is a compelling story for investors who value strategic clarity and strong clinical evidence.This quarter really marks a new strategy and journey for Hansa.